Tel> 82-32-822-8825

©2019 by Uppthera. Proudly created with Wix.com

Microscope

UPPTHERA

Synthesize Possibilities, Degrade Despair

UPPthera Inc is a pharmaceutical venture company aiming for new drug development based on PROTAC technology

 
 

Chief Executive Officer
/ Co-Founder

SI WOO CHOI

Education> Ph.D. Sungkyunkwan Univ. / Dept. of Biotechnology
Experiences> Celltrion Inc. / BIONEER corp.

RESEARCH & DEVELOPMENT

Market driven R&D  /  Risk taking advance  /  Persistent Exploration

Molecule

PROTAC

PROTAC (Proteolysis Targeting Chimaera) is next generation target protein degaradation platform employing ubiquitin-proteasome system in the body.

PROTAC consists of two linked protein binding molecules, one capable of engaging an E3 ubiquitin ligase and the other to a target protein meant for degradation. 

TARGET DISEASES

UPPthera initially focuses on solving the certain unmet needs in the Metabolic disease and several cancers including hematologic malignancy, employing PROTAC technology.

Microscope
 

CONTACT US

(21988) ​인천광역시연수구 송도미래로9 BRC 연구소 1동 204호

Tel> 82-32-822-8825

Fax> 82-32-822-8826